Product Datasheet

JS6

Catalog No. **BP-02112** · CAS **950244-33-4** · Form **free base** · Physical state **solid** · Color **White to off-white** · Version **1.0** · Revision **2026-09-02**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
NF-κB	**Cancer**

Molecular formula	**$C_{20}H_{22}FN_3O_3$**
Molecular weight	**371.4054**

STRUCTURE



DESCRIPTION

JS6 is a Bcl3 inhibitor, and inhibits Bcl3-NF-kB1 binding. JS6 inhibits tumor cell growth in vitro and in vivo.

BIOLOGICAL ACTIVITY

In Vitro

JS6 potently inhibits Bcl3 activity in cancer cells, reducing Bcl3-NF-κB1 binding, tumor colony formation, and cancer cell migration[1].

JS6 (Compound 1a) (24 h) reduces the viability of MCF-10A, MDA-MB-231 and SKBR3 breast cancer cells[2].

JS6 (24 h pre-incubation followed by 24 h chamber incubation) reduces the motility of MDA-MB-231 cells overexpressing Bcl-3[2].

JS6 (24 h) inhibits the binding of Bcl-3 to p50 in HEK-293 cells overexpressing FLAG-tagged Bcl-3[2].

JS6 (pre-incubated for 24 h, followed by 48 h of incubation after transfection) inhibits the NF-κB signaling pathway in Bcl-3-overexpressing MDA-MB-231 cells, Bcl-3-overexpressing HEK-293 cells, and HEK-293 cells overexpressing both Bcl-3 and p52[2].

SOLUBILITY

Soluble in DMSO : 50 mg/mL

REFERENCES

[1]. Soukupová J, et al. The Discovery of a Novel Antimetastatic Bcl3 Inhibitor. Mol Cancer Ther. 2021;20(5):775-786.

[2]. Westwell, A. D. (2015). 2-Benzoylaminobenzamide derivatives as BCL-3 inhibitors (PCT Patent No. WO2015014972A1). WIPO.